化合物PAM3CSK4 TFA
| 中文名称 | 化合物PAM3CSK4 TFA |
|---|---|
| 中文同义词 | 化合物PAM3CSK4 TFA;S-(2,3-双(十六酰氧)丙基)-N-十六酰-L-半胱氨酰-L-丝氨酰-L-赖氨酰-L-赖氨酰-L-赖氨酰-L-赖氨酸 三(三氟乙酸盐) |
| 英文名称 | Pam3Cys-Ser-(Lys)4 TFA |
| 英文同义词 | Pam3CSK4 TFA;Pam3Cys-Ser-(Lys)4 TFA;Pam3CSK4 TFA (112208-00-1 free base);Pam3CSK4 TFA (112208001 free base),Pam3CSK4,Toll-like Receptor (TLR),Pam-3CSK4 TFA (112208-00-1 free base),Inhibitor,inhibit,Pam3CSK4 TFA (112208 00 1 free base);S-(2,3-Bis(palmitoyloxy)propyl)-N-palmitoyl-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl-L-lysine tri(trifluoroacetate salt) |
| CAS号 | 112208-01-2 |
| 分子式 | C83H157F3N10O15S |
| 分子量 | 1624.28 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 112208-01-2.mol |
| 结构式 |  |
化合物PAM3CSK4 TFA 性质
| 储存条件 | -20°C, away from moisture |
|---|---|
| 溶解度 | 二甲基亚砜：≥ 50 mg/mL（26.99 mM） |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
Pam3CSK4 TFA 是一种 Toll 样受体 1/2 (TLR1/2) 激动剂，对人 TLR1/2 的 EC50 为 0.47 ng/mL。
Pam3CSK4 is a TLR1/2 heterodimer recognises triacylated lipopeptides.
Pam3CSK4 (1 μg/mL) enhances the antibacterial functions of granulocyte macrophage-colony stimulating factor (GM-CSF) induced neutrophils to Methicillin-resistant
Staphylococcus aureus
(MRSA).
Pam3CSK4 (5 mg/kg; i.p.; once a day for 9 days) alters brain, spleen and liver weights in neonatal mice.
| Animal Model: | Time-mated pregnant C57BL/6 wild-type mice; B6.129-Tlr2 tm1Kir /J (TLR2 -deficient) mice |
| Dosage: | 5 mg/kg |
| Administration: | Intraperitoneally (i.p.); once a day for 9 days |
| Result: | After repeated administration from postnatal day (PND3) to PND11, brain weight was decreased compared with endotoxin-free saline-treated animals at PND12. Decreased volume of cerebral gray matter, white matter in the forebrain and cerebellar molecular layer that was accompanied by an increase in spleen and liver weight at PND12. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-P1180A | 化合物PAM3CSK4 TFA Pam3CSK4 TFA | 112208-01-2 | 1mg | 1350元 |
| 2025/12/22 | HY-P1180A | 化合物PAM3CSK4 TFA Pam3CSK4 TFA | 112208-01-2 | 5 mg | 3650元 |